- Home
- EPRT vs RYTM Comparison
EPRT vs RYTM Comparison
Compare EPRT & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPRT
- RYTM
- Stock Information
- Founded
- EPRT 2016
- RYTM 2008
- Country
- EPRT United States
- RYTM United States
- Employees
- EPRT N/A
- RYTM N/A
- Industry
- EPRT Real Estate Investment Trusts
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- EPRT Real Estate
- RYTM Health Care
- Exchange
- EPRT Nasdaq
- RYTM Nasdaq
- Market Cap
- EPRT 6.2B
- RYTM 5.9B
- IPO Year
- EPRT 2018
- RYTM 2017
- Fundamental
- Price
- EPRT $30.88
- RYTM $87.82
- Analyst Decision
- EPRT Buy
- RYTM Strong Buy
- Analyst Count
- EPRT 13
- RYTM 13
- Target Price
- EPRT $34.83
- RYTM $89.77
- AVG Volume (30 Days)
- EPRT 2.1M
- RYTM 1.0M
- Earning Date
- EPRT 07-23-2025
- RYTM 08-05-2025
- Dividend Yield
- EPRT 3.82%
- RYTM N/A
- EPS Growth
- EPRT N/A
- RYTM N/A
- EPS
- EPRT 1.16
- RYTM N/A
- Revenue
- EPRT $475,463,000.00
- RYTM $136,863,000.00
- Revenue This Year
- EPRT $21.90
- RYTM $37.47
- Revenue Next Year
- EPRT $16.76
- RYTM $71.16
- P/E Ratio
- EPRT $26.60
- RYTM N/A
- Revenue Growth
- EPRT 25.32
- RYTM 48.88
- 52 Week Low
- EPRT $27.44
- RYTM $40.61
- 52 Week High
- EPRT $34.88
- RYTM $94.80
- Technical
- Relative Strength Index (RSI)
- EPRT 36.87
- RYTM 71.18
- Support Level
- EPRT $30.21
- RYTM $87.86
- Resistance Level
- EPRT $30.83
- RYTM $92.14
- Average True Range (ATR)
- EPRT 0.58
- RYTM 3.57
- MACD
- EPRT -0.11
- RYTM 1.01
- Stochastic Oscillator
- EPRT 16.95
- RYTM 77.38
About EPRT Essential Properties Realty Trust Inc.
Essential Properties Realty Trust Inc is a real estate investment trust. It is an internally managed real estate company acquires, owns and manages single-tenant properties that are net leased on a long-term basis to middle-market companies operating service-oriented or experience-based businesses. The Company generally invests in and leases freestanding, single-tenant commercial real estate facilities where a tenant services its customers and conducts activities that are essential to the generation of the tenant's sales and profits.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.